Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States
Year: 2026
Type: article
Study design: Observational Study
Abstract: Arthur Voegel,1 Ronaldo R Naranjo Jr,2 Lilian Diaz,3 Claire Vanden Eynde,3 Yuxi Wang,3 Dominic Pilon,3 Carmela Benson,2 Leslie Citrome4 1Analysis Group, Inc., New York, NY, USA; 2Johnson & Johnson, Titusville, NJ, USA; 3Analysis Group, ULC, Montreal, QC, Canada; 4Department of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla, NY, USACorrespondence: Arthur Voegel, Email [email protected]: Antipsychotic (AP) medication adherence is important for the management of schizophrenia. This study thus aimed to evaluate prescriber- and patient-level characteristics and long-acting injectable (LAI) treatment use among patients with schizophrenia to determine the association between these factors and AP adherence.Patients and methods: Adult patients with schizophrenia in the United States were identified from Komodo Research Data (01/01/2016-06/30/2023). Patients were required to have been initiated on an oral or LAI AP (index date) during the intake period (07/01/2021-06/30/2022), by a provider who prescribed APs to ≥ 6 patients with schizophrenia over the intake period (index prescriber). Providers were characterized using quartiles of the proportion of LAIs over all APs prescribed during the intake period (non-LAI prescribers; Q1: low, ≤ 8.5% LAIs; Q2-3: intermediate, > 8.5% and < 27% LAIs; Q4: high, ≥ 27% LAIs). Adherence to any AP (proportion of days covered ≥ 80%) was reported over the fixed 12-month follow-up period, and factors associated with adherence were evaluated using multivariate logistic regression.Results: In total, 22,255 patients were included (mean age: 40.9; male: 66%; Medicaid: 76%). At index, 82% and 18% of patients were initiated on an oral AP or LAI, respectively, with 10%, 21%, 47%, and 22% of index APs prescribed by non-, low-, intermediate-, and high-LAI prescribers, respectively. Prescription of the index AP by an intermediate- or high- LAI prescriber was associated with 39% and 63% higher odds of adherence, respectively, relative to non-LAI prescribers (both p< 0.001). Prescription of an LAI versus oral index AP was associated with 25% higher odds of adherence (p< 0.001). Patients of all racial/ethnic minorities had lower odds of adherence relative to White patients (all p< 0.050).Conclusion: Adherence was higher among patients treated by high-LAI prescribers, indicating that familiarity with LAI treatment and awareness of adherence challenges may improve adherence rates among patients with schizophrenia.Keywords: claims data, long-acting injectable, mental health, real-world outcomes
Language: English
Subfield: Family Practice
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7130484713
FWCI:
Cites:
Cited by:
Related to: